Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod
- 27 October 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (6), 1083-1092
- https://doi.org/10.1002/cpt.877
Abstract
Ponesimod is a selective sphingosine-1-phosphate-1 (S1P1) receptor modulator currently under investigation for the treatment of multiple sclerosis. S1P receptor modulators reduce heart rate following treatment initiation. This effect disappears with repeated dosing, enabling development of innovative up-titration regimens to optimize patient safety. There are currently no published pharmacokinetic/pharmacodynamic models describing the heart rate reduction of S1P receptor modulators in humans. The model developed here provides quantification of this effect for ponesimod. A direct-effect Imax model with estimated maximum reduction of 45%, tolerance development, and circadian variation best described this effect. The pooled data from 9 clinical studies enabled characterization of inter-individual variability. The model was used to simulate different treatment regimens to compare the effect of high initial doses versus gradual up-titration with respect to the occurrence of bradycardia. Results indicate a better safety profile when using gradual up-titration. The model allows studying dosing regimens not clinically tested in silico.This publication has 29 references indexed in Scilit:
- Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulatorsExpert Opinion on Drug Metabolism & Toxicology, 2016
- Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet, 2014
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1receptor modulator: Favorable impact of dose up-titrationThe Journal of Clinical Pharmacology, 2014
- Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first‐in‐human studyBritish Journal of Clinical Pharmacology, 2013
- The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue InflammationJournal of Pharmacology and Experimental Therapeutics, 2011
- Sphingosine-1-phosphate receptor signalling in the heartCardiovascular Research, 2008
- Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacologyPharmacology & Therapeutics, 2007
- Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P GradientsScience, 2005
- Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1Nature, 2004